Biomerica, Inc.
2.7900-0.14 (-4.78%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · BMRA · USD
Key Stats
Market Cap
8.22MP/E (TTM)
-Basic EPS (TTM)
-1.53Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
Biomerica's Q1 FY2026 revenue fell 24% y/y to $1.38M, driven by softer clinical lab and contract manufacturing demand, yet gross profit climbed 47% to $424K on a 15-point margin expansion to 30.7% from efficiency gains and lower labor costs post-reduction in force. Operating loss narrowed 18% y/y to $1.12M, aided by 29% cuts in R&D spending, while a one-time $1.1M Employee Retention Credit refund flipped net results to a $2K profit—versus a $1.32M loss last year—yielding $0.00 diluted EPS on 2.64M shares. Cash swelled 27% q/q to $3.05M after $920K from ATM stock sales, though operations burned $268K; no debt burdens the balance sheet. One customer took 48% of sales. Going concern doubts linger amid funding needs. Competition from bigger players with deeper pockets remains a key risk.
8-K
Biomerica appoints diagnostics veteran
Biomerica expanded its board to six members on October 7, 2025, appointing Gary Huff, former CEO of LabCorp Diagnostics, as an independent director with over 35 years in laboratory testing and diagnostics. He joins the Audit, Compensation, and Nominating Committees, earning an annualized $45,000 cash fee, while Dr. Jane Emerson opted not to seek re-election at the December 12, 2025 annual meeting, shrinking the board back to five. Huff's expertise bolsters strategic growth in innovative products like inFoods IBS, which showed 59.6% abdominal pain reduction in a June 2025 study. This adds seasoned leadership amid expansion efforts.
10-K
FY2025 results
Biomerica's FY2025 revenue dipped 2% to $5.3 million from $5.4 million in FY2024, with over-the-counter sales plunging 26% amid tariff pressures, yet contract manufacturing surged 44% to $1.1 million, buoyed by inFoods IBS demand. Gross margins narrowed to 91% from 89% as higher inFoods costs offset labor savings, while operating expenses plunged 20% to $5.6 million via a 15% workforce cut and slashed R&D. Cash burned $3.8 million in operations, ending at $2.4 million after netting $2.0 million from ATM equity sales; backlog doubled to $1.3 million, mostly Asia-bound. No dividends or buybacks; capex stayed minimal at $37,000 for patents. Q4 momentum flickered with IBS physician uptake, but going concern doubts linger. Reliance on a single distributor for 31% of sales risks quarterly volatility.
8-K
Biomerica appoints finance expert Chin
Biomerica replaced board member Cathy Coste with Eric Chin on June 4, 2025, after her amicable resignation. Chin, a seasoned CFO with over 20 years in healthcare finance including a $60 million raise at Akido Labs, steps in as independent director, Audit Committee Chair, and committee member. This bolsters governance amid scaling commercialization. No disagreements marked Coste's exit.
8-K
Biomerica enacts 1-for-8 split
Biomerica implemented a 1-for-8 reverse stock split, effective April 21, 2025, slashing outstanding shares from 20,366,095 to 2,545,762 to boost the bid price and meet Nasdaq's minimum requirement. Approved by shareholders in December 2024, the move preserves authorized shares while rounding up fractions for whole shares. Trading resumes split-adjusted under BMRA with new CUSIP 09061H406. Yet risks linger in volatile markets.
ABT
Abbott Laboratories
124.43-2.18
BBNX
Beta Bionics, Inc.
26.79+2.51
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
BJDX
Bluejay Diagnostics, Inc.
2.29+0.08
BRKR
Bruker Corporation
37.74-0.98
CODX
Co-Diagnostics, Inc.
0.49-0.08
INBS
Intelligent Bio Solutions Inc.
0.95-0.06
LUCD
Lucid Diagnostics Inc.
1.25-0.02
OSUR
OraSure Technologies, Inc.
2.79-0.08
ZOMDF
Zomedica Corp.
0.07+0.00